Last reviewed · How we verify

NCT03501628: MPS

Leucine or Protein Supplementation and Resistance Training

Completed NA Last updated 18 April 2018
What this trial tests

NA trial testing Placebo in Skeletal Muscle in 89 participants. Completed in 17 August 2017.

Timeline
17 August 2016
Primary endpoint
17 May 2017
17 August 2017

Quick facts

Lead sponsorAuburn University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment89
Start date17 August 2016
Primary completion17 May 2017
Estimated completion17 August 2017

Drugs / interventions tested

Conditions studied

Sponsor

Auburn University

Who can join

Adults 19 to 35, male only, with Skeletal Muscle. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to determine the effects of L-leucine (LEU) or different protein supplements standardized to LEU (\~3.0 g/serving) on changes in body composition, strength, and histological attributes in skeletal muscle and adipose tissue. Seventy-five untrained, college-aged males (mean±SE; age=21±1 yr, body mass=79.2±0.3 kg) were randomly assigned to an isocaloric, lipid-, and organoleptically-matched maltodextrin placebo (PLA, n=15), LEU (n=14), whey protein concentrate (WPC, n=17), whey protein hydrolysate (WPH, n=14), or soy protein concentrate (SPC, n=15) group. Participants performed whole-body resistance training three days per week for 12 weeks while consuming supplements twice daily. Skeletal muscle and subcutaneous (SQ) fat biopsies were obtained at baseline (T1) and \~72 h following the last day of training (T39). Tissue samples were analyzed for changes in type I and II fiber cross sectional area (CSA), non-fiber specific satellite cell count, and SQ adipocyte CSA. On average, all supplement groups including PLA exhibited similar training volumes and experienced statistically similar increases in total body skeletal muscle mass determined by dual x-ray absorptiometry (+2.2 kg; time p=0.024) and type I and II fiber CSA increases (+394 µm2 and +927 µm2; time p\<0.001 and 0.024, respectively). Notably, all groups reported increasing Calorie intakes \~600-800 kcal/d from T1 to T39 (time p\<0.001), and all groups consumed at least 1.1 g/kg/d of protein at T1 and 1.3 g/kg/d at T39. There was a training, but no supplementation, effect regarding the reduction in SQ adipocyte CSA (-210 µm2; time p=0.001). Interestingly, satellite cell counts within the WPC (p\<0.05) and WPH (p\<0.05) groups were greater at T39 relative to T1. In summary, LEU or protein supplementation (standardized to LEU content) does not provide added benefit in increasing whole-body skeletal muscle mass or strength above PLA following 3 months of training in previously untrained college-aged males that increase Calorie intakes with resistance training and consume above the recommended daily intake of protein throughout training. However, whey protein supplementation increases skeletal muscle satellite cell number in this population, and this phenomena may promote more favorable training adaptations over more prolonged periods.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Skeletal muscle mitochondrial volume and myozenin-1 protein differences exist between high versus low anabolic responders to resistance training.
    Roberts MD, Romero MA, Mobley CB, Mumford PW, et al · · 2018 · cited 40× · PMID 30065891 · DOI 10.7717/peerj.5338
  2. Soy protein supplementation is not androgenic or estrogenic in college-aged men when combined with resistance exercise training.
    Haun CT, Mobley CB, Vann CG, Romero MA, et al · · 2018 · cited 15× · PMID 30042516 · DOI 10.1038/s41598-018-29591-4

Verify or expand the search:

Other recruiting trials for Skeletal Muscle

Currently open trials in the same condition.

Other Auburn University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03501628.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing